Aug 28, 2023 By Ivy Chen Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023
Jun 28, 2023 By Ivy Chen Robert Andtbacka, MD, CM joins HiFiBiO Therapeutics as Chief Medical Officer
Jun 23, 2023 By Ivy Chen HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
Jun 14, 2023 By Ivy Chen HiFiBiO Therapeutics CEO Liang Schweizer Shares Her Professional Journey and the Company’s Pioneering DIS® Approach on the Biotech2050 Podcast
Apr 7, 2023 By Ivy Chen HiFiBiO Therapeutics Announces Oral Presentation at 2023 American Association for Cancer Research (AACR) Annual Meeting
Mar 6, 2023 By Vincent Tse Going Global: Insights on the Advantages of Biotech Globalization Published in Drug Discovery Today from HiFiBiO Therapeutics
Jan 6, 2023 By Vincent Tse HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
Jan 5, 2023 By Vincent Tse HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by Life Science Success Podcast
Nov 18, 2022 By sarahjibrin HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
